Thoracic tumor
Conditions
Interventions
S1 Group:20ml of 0.1mg/kg Esketamine+0.375% ropivacaine were injected into the thoracic 5 and 6 paravertebral spaces under the guidance of thoracoscopy
S2 Group:20ml of 0.2mg/kg Esketamine+0.375% ropivacaine were injected into the thoracic 5 and 6 paravertebral spaces under the guidance of thoracoscopy
S3 Group:20ml of 0.3mg/kg Esketamine+0.375% ropivacaine were injected into the thoracic 5 and 6 paravertebral spaces under the guidance of thoracoscopy
Sponsors
Ningbo Medical Center Li Huili hospital
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients aged 20-75 years old, classified by the American Society of Anesthesiologists (ASA) as Grade I-II, without neurological or muscular disorders, spinal deformities, fractures, trauma, or surgical history, who agreed to participate in this study.
Exclusion criteria
Exclusion criteria: Allergies to ropivacaine and Esketamine, abnormal coagulation function, history of spinal deformities, fractures, injuries, or surgeries, history of thoracic aortic aneurysm, failure to cooperate or request withdrawal during the research process
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Duration of sensory blockade;Postoperative analgesia;Postoperative adverse reactions; | — |
Primary
| Measure | Time frame |
|---|---|
| Rest and exercise (deep breathing or coughing) NRS score and Ramsay sedation score; | — |
Countries
China
Contacts
Public ContactLihong Hu
Ningbo Medical Center Li Huili hospital
Outcome results
None listed